Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Mahta Mortezavi, a Clinical Director for Drug Discovery and Early Development as part of the Anti-infectives Research Unit at Pfizer, as they discuss her recent paper ‘Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumour necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.’
